HER2-positive breast cancer is a type of breast cancer in which the cancer cells have too many copies of a gene called HER2, causing them to produce an excess of a protein that drives rapid cell growth. It accounts for roughly 15 to 20% of all breast cancer diagnoses. While HER2-positive cancers tend to be more aggressive than some other types, they also respond to highly effective targeted treatments that have dramatically improved survival over the past two decades.
How HER2 Fuels Cancer Growth
Every healthy cell carries a small number of HER2 genes and produces a modest amount of the HER2 protein on its surface. This protein acts as a growth signal receiver: when it pairs up with similar proteins on the cell membrane, it triggers internal pathways that tell the cell to divide, survive, and form new blood vessels. In normal tissue, this process is tightly regulated.
In HER2-positive breast cancer, something goes wrong at the genetic level. Instead of the normal two copies, a tumor cell can carry 25 to 50 copies of the HER2 gene. That amplification floods the cell surface with protein, sometimes reaching 2 million receptors on a single cell, roughly 40 to 100 times the normal amount. With that many receptors firing growth signals simultaneously, the cell divides uncontrollably and resists the normal checkpoints that would slow it down. The HER2 protein also degrades a key molecule that acts as a brake on cell division, removing yet another safeguard.
Researchers believe this gene amplification happens early, often appearing in pre-invasive (in situ) tumors before they spread. Once established, HER2 status generally stays the same as the cancer progresses to lymph nodes or distant sites.
How HER2 Status Is Tested
After a breast biopsy, pathologists test the tissue sample to determine how much HER2 protein is present and whether the gene itself is amplified. Two main tests are used, sometimes in sequence.
The first is immunohistochemistry (IHC), which stains the tissue to reveal HER2 protein on cell surfaces. Results are scored on a 0 to 3+ scale:
- 0: No staining, or faint incomplete staining in fewer than 10% of cancer cells. Considered HER2-negative.
- 1+: Faint incomplete staining in more than 10% of cells. Now classified as HER2-low.
- 2+: Weak to moderate complete staining in more than 10% of cells. Considered equivocal, meaning a second test is needed.
- 3+: Strong, complete staining around the entire membrane of more than 10% of cells. This is HER2-positive.
When the IHC result is 2+ (equivocal), a second test called FISH (fluorescence in situ hybridization) checks whether the HER2 gene itself is amplified. If FISH confirms amplification, the cancer is classified as HER2-positive. If not, it falls into the HER2-low category.
What HER2-Low Means
HER2-low is a relatively new classification that has become clinically important in recent years. It includes cancers with an IHC score of 1+, or an IHC score of 2+ that tests negative for gene amplification on FISH. These tumors have some HER2 protein on their surface, just not enough to qualify as HER2-positive.
This distinction matters because a newer class of targeted drug, called an antibody-drug conjugate, can latch onto even small amounts of HER2 protein and deliver chemotherapy directly into those cells. In a landmark clinical trial published in the New England Journal of Medicine (DESTINY-Breast04), patients with HER2-low metastatic breast cancer who received this type of targeted treatment had a median progression-free survival of 9.9 months compared to 5.1 months with standard chemotherapy. Overall survival was 23.4 months versus 16.8 months. The risk of death dropped by 36%. These results mean that the difference between a score of 0 and 1+ now affects which treatments you may be eligible for.
HER2-Positive Subtypes
Not all HER2-positive breast cancers are identical. About half also test positive for hormone receptors (estrogen and/or progesterone), a combination sometimes called triple-positive breast cancer. The other half are HER2-positive but hormone receptor-negative.
Triple-positive cancers have two separate fuel sources: HER2 protein and hormones. That might sound worse, but it actually means there are more treatment targets. Patients typically receive both HER2-targeted therapy and hormone therapy, attacking the cancer on two fronts. Hormone therapy usually involves a daily pill taken for at least five years, sometimes longer, because hormone receptor-positive cancers can recur years after initial treatment.
HER2-positive, hormone receptor-negative cancers rely primarily on HER2 for growth. Treatment focuses on targeted therapy combined with chemotherapy, without the long-term hormone-blocking medication.
Treatment and What to Expect
The backbone of HER2-positive treatment is targeted therapy, which blocks the HER2 protein from sending growth signals. The most widely used approach involves monoclonal antibodies delivered through an IV, typically given alongside chemotherapy. Treatment plans vary by stage, but targeted therapy in the early-stage (adjuvant) setting generally lasts about one year.
Other types of HER2-targeted drugs include tyrosine kinase inhibitors (taken as pills) and antibody-drug conjugates, which combine a targeting antibody with a chemotherapy payload so the drug is delivered more precisely to cancer cells. Your oncologist will select among these based on cancer stage, whether the cancer has spread, and how it responds to initial treatment.
One important consideration with HER2-targeted therapy is heart health. These drugs can affect the heart’s pumping ability in some patients. Heart function is typically monitored with imaging before treatment starts, every three months during treatment, and every six months for at least two years afterward. If heart function dips below a certain threshold or symptoms like shortness of breath develop, treatment may be paused to allow recovery. For most patients, any cardiac effects are reversible once the drug is stopped or adjusted.
Survival and Outlook
Before targeted therapies existed, HER2-positive breast cancer carried a worse prognosis than HER2-negative types because of its aggressive growth pattern. That picture has changed substantially. According to data from the U.S. National Cancer Institute, more than 90% of people with HER2-positive breast cancer are alive five years after diagnosis. Outcomes are strongest when the cancer is caught at a local or regional stage.
Even in the metastatic setting, newer drugs have extended survival significantly. The combination of multiple targeted therapies and antibody-drug conjugates means that patients who stop responding to one treatment often have additional options available. For triple-positive cancers, the added benefit of hormone therapy provides another layer of long-term disease control.
HER2 status is one of the most actionable pieces of information in a breast cancer diagnosis. It directly determines which treatments are available, and those treatments are among the most effective in oncology today.